

**NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.**

15 October 2024

**Oxford Nanopore Technologies plc ("Oxford Nanopore" or "the Company")**

**Issue of Equity and Total Voting Rights**

The Company today announces in respect of the period from 1 October to 14 October 2024, the issue of 12,566,031 ordinary shares of £0.0001 each, following:

- the issue of 12,500,789 ordinary shares to satisfy the vesting of awards under the Oxford Nanopore Technologies Limited Long-Term Incentive Plan 2021; and
- the exercise of options granted under the Company's share option plans and issuance of shares under certain of the Company's remuneration schemes and such ordinary shares were admitted to the Official List of the Financial Conduct Authority ("FCA") and to trading on the London Stock Exchange's main market for listed securities under the Company's block listing facility. Following this issue, the Company has the ability to admit a further 65,242 ordinary shares under its block listing facility.

In accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6.1, the Company announces that as at 14 October 2024, the Company's issued share capital consisted of 954,021,220 ordinary shares, one class A limited anti-takeover ("LAT") share of £1.00, one class B LAT share of £1.00 and one class C LAT share of £1.00 and the Company will not hold any shares in treasury. Only the ordinary shares are voting shares and each such ordinary share carries one vote per ordinary share. As outlined in the Company's IPO Prospectus, the LAT shares could carry their rights for up to three years from the date of admission. Therefore, on 5 October 2024, the LAT shares ceased to carry any of their rights. Accordingly, the total number of voting rights in the Company as at 14 October 2024 is 954,021,220. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information, please contact:

**Oxford Nanopore Technologies plc**

Investors: [ir@nanoporetech.com](mailto:ir@nanoporetech.com)

Media: [media@nanoporetech.com](mailto:media@nanoporetech.com)

**Teneo (communications adviser to the Company)**

Tom Murray, Olivia Peters

+44 (0) 20 7353 4200

[OxfordNanoporeTechnologies@teneo.com](mailto:OxfordNanoporeTechnologies@teneo.com)

**About Oxford Nanopore Technologies plc:**

Oxford Nanopore Technologies' goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for real-time, high-performance, accessible and scalable analysis of DNA and RNA. The technology is used in more than 120 countries to understand the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses and whole environments. Oxford Nanopore Technologies products are intended for molecular biology applications and are not intended for diagnostic purposes.

[www.nanoporetech.com](http://www.nanoporetech.com)

**Forward-looking statements**

This announcement contains certain forward-looking statements. For example, statements regarding expected revenue growth and profit margins are forward-looking statements. Phrases such as "aim", "plan", "expect", "intend", "anticipate", "believe", "estimate", "target", and similar expressions of a future or forward-looking nature should also be considered forward-looking statements. Forward-looking statements address our expected future business and financial performance and financial condition, and by definition address matters that are, to different degrees, uncertain. Our results could be affected by macroeconomic conditions, the COVID-19 pandemic, delays in our

receipt of components or our delivery of products to our customers, suspensions of large projects and/or acceleration of large products or accelerated adoption of pathogen surveillance. These or other uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TVREASESFAXLFEA